Tuesday, 15 November 2016

Investors' Prognosis for Teva Seems Overly Bleak

A rough year in generic-drug industry offers investors opportunity.

from WSJ.com: Markets http://ift.tt/2fRBnmT
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)